about
Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortalityUnraveling the message: insights into comparative genomics of the naked mole-ratThe crucial impact of lysosomes in aging and longevityInhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and BeyondDeveloping criteria for evaluation of geroprotectors as a key stage toward translation to the clinicManagement of immunosuppressant agents following liver transplantation: Less is moreAttention to Background Strain Is Essential for Metabolic Research: C57BL/6 and the International Knockout Mouse ConsortiumSignaling pathways in the development of infantile hemangiomaSestrins function as guanine nucleotide dissociation inhibitors for Rag GTPases to control mTORC1 signalingThe TSC complex is required for the benefits of dietary protein restriction on stress resistance in vivoIntermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J MiceThe Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and AgingMitochondrial hormesis and diabetic complicationsA cell-penetrating ester of the neural metabolite lanthionine ketimine stimulates autophagy through the mTORC1 pathway: Evidence for a mechanism of action with pharmacological implications for neurodegenerative pathologiesMetformin as a cellular protector; a synoptic view of modern evidencesAUTEN-67, an autophagy-enhancing drug candidate with potent antiaging and neuroprotective effectsmTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseasesRecent progress in metabolic signaling pathways regulating aging and life spanGenetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signatureThe preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agentAutophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targetingIn search of antiaging modalities: evaluation of mTOR- and ROS/DNA damage-signaling by cytometry.A Small Molecule Screen Exposes mTOR Signaling Pathway Involvement in Radiation-Induced ApoptosisThe mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer's disease.Age-related impairment of pancreatic Beta-cell function: pathophysiological and cellular mechanisms.Pathogenic role of BECN1/Beclin 1 in the development of amyotrophic lateral sclerosis.Rapamycin-induced metabolic defects are reversible in both lean and obese miceDiminished mTOR signaling: a common mode of action for endocrine longevity factors.Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system.Genetic variants near MLST8 and DHX57 affect the epigenetic age of the cerebellum.Overnutrition, mTOR signaling, and cardiovascular diseases.Lifespan modulation in mice and the confounding effects of genetic background.AMPK at the nexus of energetics and aging.AMP-activated protein kinase deficiency rescues paraquat-induced cardiac contractile dysfunction through an autophagy-dependent mechanismProteasome inhibitors activate autophagy involving inhibition of PI3K-Akt-mTOR pathway as an anti-oxidation defense in human RPE cellsThe role of TORC1 in muscle development in DrosophilaPrevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damageBoth mTORC1 and mTORC2 are involved in the regulation of cell adhesion.Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice.
P2860
Q24313010-B2BD2D35-266F-4F70-BBE1-0D20A2D52E21Q24745996-A1DEDA72-0E12-4509-8A03-618ED7BDA828Q26745908-A69F4FD6-B4DD-43E0-894C-988AD6324D33Q26749118-74906B14-CA0D-4A26-A38F-728F518E4676Q26751462-EF19C3A9-913D-441B-95EA-38E44D99773DQ26766217-E95C19A6-C902-4045-B841-83FAF7DF0B32Q26770033-104F6360-9833-4031-8E37-C343950B4533Q26773196-9B710D4B-D6F4-4C7E-9011-F304E436C979Q26996608-4A849ECF-8738-4D76-BBC3-89BE05BBEC49Q28118705-0477F637-1F46-419A-86E3-A060A4258CACQ28246133-504E76CA-9197-4F11-A178-7A86A67E556FQ28275005-3E0266F3-9621-4E5D-BDFD-9EB115188266Q28276378-591B88D7-CF5A-4C5E-A79D-3C98EB7DAB4CQ28388387-9EFA859D-F72B-429D-9D44-867B85588F90Q28388679-ABEF4860-92F3-40DC-943C-DA671B267030Q28817196-B7E35C1C-96ED-4D00-A7F7-66C443D413FEQ28834576-340073FE-596E-40BF-9DA8-3AD6AF5A646BQ30838293-C03E1584-6285-4931-8BDF-229E5F5124D1Q33616159-7E8407D6-6A41-4E68-A0EB-3A2FE3FB95D4Q33707896-BB31103A-86F2-4A51-BC23-3FB19DCC6678Q33728258-40EE1338-06F8-4EEF-9A2D-10F3F6375623Q33752594-54546F15-1A7E-485D-B45C-A140F815D4CEQ33841800-0D6FE8A0-F285-4AD3-ABE0-0B38FBD7C017Q33846025-5B3DAC03-0099-4C90-A63A-801AB64AEAC3Q33914286-9F14ED15-3750-4645-B837-830B53A1B4AEQ34127184-7C3EEF20-BA19-4A2A-8B7D-A2798E7E297DQ34373108-35E0E711-D0DE-433E-9F5D-4DC98E56CF41Q34461128-D51C716C-2828-4A72-B1F0-D93D9913A7B6Q34462362-A76A53C3-D7D2-43A4-B90A-E9923AC2B45AQ34497857-42794EDF-DFAC-4924-93BD-B16435CD4FF1Q34511671-278DBD3D-943C-4FF7-93B7-75BF41A8D150Q34519316-01D59AD2-CE4E-4B94-B01D-D5E8A4C3597EQ34642886-6340F09F-7DD8-41B6-815D-ACDECB6AB356Q34871517-EC75D6F9-A87F-4B9B-98F9-D54635A8FFC9Q35102608-195234B7-A6F0-4639-A9D6-88B043D41A34Q35213222-1A658F4D-B2B9-43EE-A7D3-74CB9C8E9B21Q35379199-484F7B1C-5C81-4586-B374-1F7B144FAAE2Q35563024-B4521D0B-DC23-4102-A3BD-9187BDA03C84Q35740165-93C148AA-CF73-4E7F-9D8F-38693399534CQ35758129-F21E08DD-C73C-4B8E-A3BF-B5CFC4CC9834
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Rapalogs and mTOR inhibitors as anti-aging therapeutics
@ast
Rapalogs and mTOR inhibitors as anti-aging therapeutics
@en
Rapalogs and mTOR inhibitors as anti-aging therapeutics
@nl
type
label
Rapalogs and mTOR inhibitors as anti-aging therapeutics
@ast
Rapalogs and mTOR inhibitors as anti-aging therapeutics
@en
Rapalogs and mTOR inhibitors as anti-aging therapeutics
@nl
prefLabel
Rapalogs and mTOR inhibitors as anti-aging therapeutics
@ast
Rapalogs and mTOR inhibitors as anti-aging therapeutics
@en
Rapalogs and mTOR inhibitors as anti-aging therapeutics
@nl
P2860
P50
P3181
P356
P1476
Rapalogs and mTOR inhibitors as anti-aging therapeutics
@en
P2093
P2860
P304
P3181
P356
10.1172/JCI64099
P407
P577
2013-03-01T00:00:00Z